ABOUT US
Welcome to NGM Bio
We are a clinical stage biopharmaceutical company advancing a robust pipeline of drug candidates to address a spectrum of large, unmet medical needs. We are focused on harnessing powerful, untapped biology underlying major diseases to develop transformative therapeutics for patients.
We are intensely science-driven and committed to having a profound impact on addressing some of today’s most urgent medical needs.
We are leveraging our biology-centric drug discovery approach to uncover novel mechanisms of action and generate proprietary insights that will enable us to move rapidly into proof-of-concept studies and deliver first-in-class medicines. We aspire to operate one of the most productive research and development engines in the biopharmaceutical industry, with multiple programs already in clinical development. Our initial areas of focus include cardio-metabolic, liver, oncologic and ophthalmic diseases. But we are not limited to the therapeutic areas we can explore. We intend to continue growing our pipeline of experimental medicines and building our proficiency in discovery research.
Our Team
Our management team, scientists, board members and advisors have extensive track records of successfully discovering, developing and delivering to patients multiple, class-defining drugs with meaningful clinical and commercial impact, which positions us well to maximize the potential of our drug discovery approach.
William J. Rieflin
Executive Chairman
David J. Woodhouse, Ph.D.
Chief Executive Officer
Jin-Long Chen, Ph.D.
Founder and Chief Scientific Officer
Alex DePaoli, M.D.
Senior Vice President, Chief Translational Officer
Marc Learned, Ph.D.
Vice President, Research Operations
Hsiao D. Lieu, M.D.
Senior Vice President, Chief Medical Officer
Siobhan Nolan Mangini
Chief Financial Officer
Brian Muma
Vice President, Human Resources
Valerie Pierce
Senior Vice President, General Counsel and Chief Compliance Officer
Hui Tian, Ph.D.
Senior Vice President, Research
Board of Directors
William J. Rieflin
Executive Chairman, NGM Biopharmaceuticals
David V. Goeddel, Ph.D.
Managing Partner, The Column Group
Jin-Long Chen, Ph.D.
Founder and Chief Scientific Officer, NGM Biopharmaceuticals
Shelly Guyer
Chief Sustainability Officer, Invitae Corporation
Carole Ho, M.D.
Chief Medical Officer & Head of Development, Denali Therapeutics
Suzanne Sawochka Hooper
Former Executive Vice President and General Counsel, Jazz Pharmaceuticals
Mark Leschly
Managing Partner, RHO Capital Partners
Roger M. Perlmutter, M.D., Ph.D.
CEO, Eikon Therapeutics
David J. Woodhouse, Ph.D.
Chief Executive Officer, NGM Biopharmaceuticals
Scientific Advisory Board
Michael S. Brown, M.D.
Chairman
Michael Fischbach, Ph.D.
Joseph L. Goldstein, M.D.
Robert D. Schreiber, Ph.D.